Press coverage about Krystal Biotech (NASDAQ:KRYS) has trended somewhat negative recently, according to Accern Sentiment. The research group ranks the sentiment of press coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Krystal Biotech earned a coverage optimism score of -0.22 on Accern’s scale. Accern also assigned news coverage about the company an impact score of 46.597820513493 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
Several equities analysts recently issued reports on KRYS shares. Ladenburg Thalmann Financial Services started coverage on Krystal Biotech in a research report on Wednesday, October 18th. They set a “buy” rating and a $23.00 price target on the stock. Zacks Investment Research lowered Krystal Biotech from a “hold” rating to a “sell” rating in a research report on Tuesday, December 19th.
Krystal Biotech (NASDAQ:KRYS) opened at $9.02 on Monday. Krystal Biotech has a 1 year low of $8.03 and a 1 year high of $11.98. The stock has a market capitalization of $90.04 and a P/E ratio of -12.36.
About Krystal Biotech
Krystal Biotech, Inc gene therapy company. The Company is engaged in developing and commercializing novel treatments for patients suffering from dermatological diseases. The Company has developed a Skin TARgeted Delivery platform, or STAR-D platform, that consists of a patent pending engineered viral vector based on herpes simplex virus 1, or HSV-1, and skin-optimized gene transfer technology, to develop off-the-shelf treatments for dermatological diseases.
Receive News & Ratings for Krystal Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Krystal Biotech and related companies with MarketBeat.com's FREE daily email newsletter.